KR900001367A - 폐의 폐색성 기능장애 및/또는 출뇨관 기능장애 치료용 약제로서 치환된 3,4-디하이드로-2h-벤조피란의 용도 - Google Patents

폐의 폐색성 기능장애 및/또는 출뇨관 기능장애 치료용 약제로서 치환된 3,4-디하이드로-2h-벤조피란의 용도 Download PDF

Info

Publication number
KR900001367A
KR900001367A KR1019890010129A KR890010129A KR900001367A KR 900001367 A KR900001367 A KR 900001367A KR 1019890010129 A KR1019890010129 A KR 1019890010129A KR 890010129 A KR890010129 A KR 890010129A KR 900001367 A KR900001367 A KR 900001367A
Authority
KR
South Korea
Prior art keywords
alkyl
treatment
compound
obstructive
dysfunction
Prior art date
Application number
KR1019890010129A
Other languages
English (en)
Inventor
크리스티안 엥글레르르 하인리히
클라우스 에릭
마니아 디터
쉴켄스 베른바르트
Original Assignee
하인리히 벡커, 베른하르트 벡크
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커, 베른하르트 벡크, 훽스트 아크티엔게젤샤프트 filed Critical 하인리히 벡커, 베른하르트 벡크
Publication of KR900001367A publication Critical patent/KR900001367A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Abstract

내용 없음

Description

폐의 페색성 기능장애 및/또는 출뇨관 기능장애 치료용 약제로서 치환된 3,4-디하이드로-2H-벤조피란의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 폐의 폐색성 기능장애 및/또는 출뇨판(effect urinary passages) 기능장애 치료용 약제 제조를 위한 일반식(I) 화합물의 용도.
    (I)
    상기 식에서, R1은 H, OH, (C1-C4)-알콕시, (C1-C2)-알킬 또는 NR4R5이고, R2및 R3는 동일하거나 상이하며, (C1-C4)-알킬을 나타내며, R4및 R5는 동일하거나 상이하며, H, (C1-C2)-알킬 또는 (C1-C3)-알킬-카보닐을 나타내고, Ar은 동일하거나 상이한 라디칼(C1-C2)-알킬, (C1-C2)-알콕시, 할록겐, 트리플루오로메틸, CN, NO2, CO-(C1-C2)-알킬 또는 SOm-(C1-C2)-알킬 1 내지 3개로 치환되거나 비치환된 방향족 또는 헤테로 방향족 시스템을 나타내며, m 및 n은 1또는 2를 나타내고, X는 헤테로 원자, O, S 또는 NR6로 차단될 수 있는 쇄(CH2)r이며, R6는 H 또는 (C1-C4)-알킬이고, r은 2,3,4, 또는 5를 나타낸다.
  2. 활성물질로서 화합물(I) 및 통상적인 첨가제를 함유하는, 폐의 폐색성 기능장애 치료용 약학적 생성물.
  3. 폐의 폐색성 기능장애 및/또는 출뇨관 기능장애 치료용 화합물(I).
  4. 제1항에 있어서, R1내지 R3및 ArSOn이 제1항에서 정의한 바와 같고, X가 (CH2)r (여기에서, r은 3 또는 4이다)인 일반식(I) 화합물의 용도.
  5. 제1항에 있어서, R1내지 R3가 제1항에서 정의한 바와 같고, Ar이 제1항에서 정의한 바와 같이 치환되거나 비치환된 페닐을 나타내며, X는 (CH2)r (여기에서, r은 3 또는 4이다)을 나타내는 일반식(I) 화합물의 용도.
  6. 제1항에 있어서, R1이 H이고, R2및 R3가 (C1-C2)-알킬이며, Ar이 (C1-C2)-알킬, (C1-C2)-알콕시 또는 할로겐에 의해 1회 치환되거나 비치환된 페닐이고, n이 2이며, X가 (CH2)r (여기에서 r은 3 또는 4이다)인 일반식(I) 화합물의 용도.
  7. 제1항에 있어서, 출뇨관 기능장애 치료를 위한 R1이 H이고, R2및 R3가 (C1-C2)-알킬이며, X가 (CH2)3이고, Ar이 C6H4Cl이며, n이 2인 일반식(I) 화합물의 용도.
  8. 제1항에 있어서, R1이 수소이고, R2및 R3는 (C1-C2)-알킬이며, Ar은 페닐이고, n은 2이며 X는 (CH2)3인 일반식(I) 화합물의 용도.
  9. 출뇨관 기능장애 치료를 위한 3,4-디하이드로-2,2-디메틸-6-(2-클로로페닐설포닐)-트랜스-4-(2-옥소-1-피롤리디닐)-2H-벤조[b]피란-3-올의 용도.
  10. 폐색성 호흡기관 기능장애 치료를 위한 3,4-디하이드로-2,2-디메틸-6-페닐설포닐-트랜스-4-(2-옥소-1-피롤리디닐)-2H-벤조[b]피란-3-올의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890010129A 1988-07-19 1989-07-18 폐의 폐색성 기능장애 및/또는 출뇨관 기능장애 치료용 약제로서 치환된 3,4-디하이드로-2h-벤조피란의 용도 KR900001367A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3824446.2 1988-07-19
DE3824446A DE3824446A1 (de) 1988-07-19 1988-07-19 Verwendung substituierter 3,4-dihydro-2h-benzopyrane als heilmittel gegen obstruktive funktionsstoerungen der lunge und/oder stoerungen der ableitenden harnwege

Publications (1)

Publication Number Publication Date
KR900001367A true KR900001367A (ko) 1990-02-27

Family

ID=6359009

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890010129A KR900001367A (ko) 1988-07-19 1989-07-18 폐의 폐색성 기능장애 및/또는 출뇨관 기능장애 치료용 약제로서 치환된 3,4-디하이드로-2h-벤조피란의 용도

Country Status (18)

Country Link
EP (2) EP0351720B1 (ko)
JP (1) JPH0273015A (ko)
KR (1) KR900001367A (ko)
AT (1) ATE110270T1 (ko)
AU (1) AU621388B2 (ko)
CA (1) CA1336891C (ko)
CZ (1) CZ417091A3 (ko)
DE (2) DE3824446A1 (ko)
DK (1) DK171782B1 (ko)
ES (1) ES2061816T3 (ko)
FI (1) FI893460A (ko)
HU (1) HU210149B (ko)
IE (1) IE63872B1 (ko)
IL (1) IL91015A (ko)
NZ (1) NZ229961A (ko)
PH (1) PH26696A (ko)
PT (1) PT91197B (ko)
ZA (1) ZA895459B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403548A (en) * 1992-02-28 1995-04-04 Takeda Chemical Industries Ltd. Activated carbon adsorbent and applications thereof
KR100475147B1 (ko) * 2002-09-09 2005-03-10 정의상 알루미나 분진 중의 유해가스 제거를 위한 탈취제 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW244350B (ko) * 1991-12-14 1995-04-01 Hoechst Ag
HUT72741A (en) * 1992-12-19 1996-05-28 Alkaloida Vegyeszeti Gyar Method for producing benzopyrane derivatives and pharmaceutical compositions containing them
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
EP1244426A4 (en) * 1999-12-23 2004-10-06 Robert E Coifman METHODS AND FORMULATIONS FOR THE EFFICIENT ADMINISTRATION OF WATER-INSOLUBLE MEDICINES BY MEANS OF A NEBULIATOR
MXPA05004668A (es) 2002-11-12 2005-06-08 Warner Lambert Co Procedimiento de estimulacion de crecimiento de pelo usando benzopiranos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107423B1 (en) * 1982-10-19 1986-07-23 Beecham Group Plc Novel chromans and chromenes
GB8419515D0 (en) * 1984-07-31 1984-09-05 Beecham Group Plc Treatment
GB8513369D0 (en) * 1985-05-28 1985-07-03 Beecham Group Plc Treatment
DE3881714D1 (de) * 1987-02-04 1993-07-22 Hoechst Ag Alkylsubstituierte n-benzopyranyllactame, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
DE3703227A1 (de) * 1987-02-04 1988-08-18 Hoechst Ag Substituierte 3,4-dihydro-2h-benzopyrane, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403548A (en) * 1992-02-28 1995-04-04 Takeda Chemical Industries Ltd. Activated carbon adsorbent and applications thereof
KR100475147B1 (ko) * 2002-09-09 2005-03-10 정의상 알루미나 분진 중의 유해가스 제거를 위한 탈취제 조성물

Also Published As

Publication number Publication date
AU621388B2 (en) 1992-03-12
PH26696A (en) 1992-09-15
DK355489D0 (da) 1989-07-18
DK171782B1 (da) 1997-05-26
PT91197A (pt) 1990-02-08
FI893460A (fi) 1990-01-20
EP0560399A1 (de) 1993-09-15
IE892323L (en) 1990-01-19
DE3824446A1 (de) 1990-01-25
NZ229961A (en) 1991-11-26
IE63872B1 (en) 1995-06-14
IL91015A (en) 1994-11-28
DK355489A (da) 1990-01-20
EP0351720A3 (de) 1992-01-02
HUT55988A (en) 1991-07-29
CZ417091A3 (en) 1993-02-17
PT91197B (pt) 1995-07-18
DE58908228D1 (de) 1994-09-29
FI893460A0 (fi) 1989-07-17
EP0351720B1 (de) 1994-08-24
ZA895459B (en) 1990-03-28
CA1336891C (en) 1995-09-05
HU210149B (en) 1995-02-28
ES2061816T3 (es) 1994-12-16
EP0351720A2 (de) 1990-01-24
AU3818989A (en) 1990-01-25
JPH0273015A (ja) 1990-03-13
ATE110270T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
ATE169008T1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
HUP0102295A2 (hu) Citokinek által közvetített betegségek kezelésére alkalmas benzamid-származékok
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
ATE396988T1 (de) Chinolin- und chianzolinderivate zur behandlung von tumoren
DK0462812T3 (da) Pyranderivater som inhibitorer af 5-lipoxygenase
DE3471933D1 (de) Phenoxyalkoxy-3,4-dihydro-2h-1-benzopyran derivatives
ATE25977T1 (de) Furanonderivate, verfahren zu ihrer herstellung und ihre verwendung.
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR900006347A (ko) 살균성 플루오로퀴놀로닐 세펨
KR900001367A (ko) 폐의 폐색성 기능장애 및/또는 출뇨관 기능장애 치료용 약제로서 치환된 3,4-디하이드로-2h-벤조피란의 용도
DE69312567T2 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
HUP9901247A2 (hu) Naftimidazol-, naftoxazol- és naftotiazol-dion-származékok alkalmazása érrendszeri elváltozások okozta betegségek kezelésére szolgáló gyógyszerkészítmények előállítására, valamint új származékok
SE9904177D0 (sv) Novel compounds
ES8505993A1 (es) Un metodo para preparar un derivado de 3-indolcarboxamida
HUP0300391A2 (hu) Prosztaglandinnal rokon vegyületek alkalmazása szemen belüli túlnyomás és glaukóma kezelésére alkalmas készítmény előállítására
DE69619088T2 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
KR950701636A (ko) 피리도티아진초산 화합물, 그의 제조방법 및 그의 용도(pyridothiazineacetic acid compound, process for producing the same, and use thereof]
DE69716939T2 (de) 2-carbonylthiazolderivate und ihre verwendung
AR030879A1 (es) Uso de derivados del acido hidroperoxieicosatetraenoico luego de cirugia refractiva
KR910021377A (ko) 디하이드로피리딘 화합물의 용도
KR890011593A (ko) 쇼크 치료에 사용하기 위한 2-(페닐아미노)이미디졸린-(2)의 용도
KR950017956A (ko) N-치환 아자비시클로헵탄 유도체, 그의 제조 방법 및 용도
DE69424677T2 (de) Präparat zur behandlung der drogenabhängigkeit

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application